A novel vaccine formaultion to prevent birth defects

预防出生缺陷的新型疫苗配方

• 批准号: nhmrc : 1076443
• 负责人: Prof Rajiv Khanna
• 金额: $ 35.4万
• 依托单位: Queensland Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: Development Grants
• 财政年份: 2014
• 资助国家: 澳大利亚
• 起止时间: 2014-01-01 至 2017-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/novel-vaccine-formaultion-birth-defects/455732
• 关键词: novel; vaccine; formaultion; prevent; birth

Congenital cytomegalovirus (CMV) infection is one of the TORCH infections (toxoplasmosis, rubella, cytomegalovirus, and herpes simplex) and is one of major cause of birth defects. Transmission of CMV infection from mother to unborn babies can lead to deafness, blindness, small head syndrome (microcephaly), seizures and mental retardation. There is an urgent need to develop an effective vaccine against CMV. This project is aiming to develop a novel CMV vaccine formulation for clinical testing in humans.

先天性巨细胞病毒（CMV）感染是TORCH感染（弓形体病、风疹、巨细胞病毒和单纯疱疹）的一种，是导致出生缺陷的主要原因之一。巨细胞病毒感染从母亲传播给未出生的婴儿可导致耳聋、失明、小头综合征（小头畸形）、癫痫发作和智力迟钝。因此，迫切需要开发一种有效的CMV疫苗。该项目旨在开发一种新型CMV疫苗制剂，用于人体临床试验。